Sanofi - American Depositary Shares (NQ:SNY)

39.72 -0.20 (-0.51%)

Delayed Quote Updated: 3:41 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

42 43 Next >

Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study ↗

March 17, 2023

Via Benzinga

SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories ↗

March 17, 2023

Benzinga

Via Benzinga

Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78% ↗

March 17, 2023

Via Benzinga

Why Provention Bio Stock Skyrocketed 256% This Week ↗

March 16, 2023

Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.

Via The Motley Fool

What's Going On With Sanofi Stock After Hours? ↗

March 16, 2023

Sanofi SA (NASDAQ: SNY) is buzzing in Thursday's after-hours session after the company said it will cut the list price of its most widely prescribed insulin in the United States

Via Benzinga

2 Top Biotech Stocks to Buy Right Now ↗

March 15, 2023

These two companies are showering shareholders with market-topping payouts.

Via The Motley Fool

Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi ↗

March 13, 2023

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

March 07, 2023

Via Benzinga

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners ↗

March 13, 2023

On a volatile market day, companies are still looking for smart combinations.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 13, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion

March 13, 2023

Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection ↗

February 24, 2023

Via Benzinga

Sanofi (SNY) Q4 2022 Earnings Call Transcript ↗

February 03, 2023

SNY earnings call for the period ending December 31, 2022.

Via The Motley Fool

Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal ↗

March 13, 2023

Pfizer expects Seagen to add at least $10 billion to its topline in 2030.

Via Investor's Business Daily

Why Provention Bio Stock Is Rocketing Past 52-Week Highs Today ↗

March 13, 2023

Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company.

Via Benzinga

Why Is Provention Bio (PRVB) Stock Up 263% Today? ↗

March 13, 2023

Provention Bio (PRVB) stock is rocketing higher on Monday following news that Sanofi (SNY) is acquiring the company for $2.9 billion.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 13, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday!

Via InvestorPlace

Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows ↗

March 13, 2023

After the market mayhem seen last week, some semblance of normalcy could return to Wall Street, thanks to the government’s move to assuage concerns in response to the banking crisis.

Via Benzinga

Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race ↗

March 08, 2023

These companies aren't working on a vaccine, but a monoclonal antibody.

Via Investor's Business Daily

7 Blue-Chip Stocks to Buy for Quality-Focused Investors ↗

March 06, 2023

With circumstances shaky in the market right now, concerned investors may want to consider blue-chip stocks to buy.

Via InvestorPlace

Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval ↗

March 06, 2023

The French drug company got the nod for a hemophilia treatment.

Via The Motley Fool

FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles ↗

March 01, 2023

Via Benzinga

Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit? ↗

March 01, 2023

Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price...

Via Benzinga

The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks ↗

February 24, 2023

Startling cancer vaccine results from Moderna may point to the next big thing in biotech.

Via Investor's Business Daily

Analyst Confidence in Eli Lilly Boosted by Product Pipeline

February 22, 2023

Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.

Via MarketBeat

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees ↗

February 17, 2023

Shares crumbled after Moderna's flu shot outperformed in just one flu strain.

Via Investor's Business Daily

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples ↗

February 03, 2023

Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.

Via Investor's Business Daily

Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact ↗

February 03, 2023

Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.